United Therapeutics Corporation (UTHR) exhibits 87.9% gross margins and 20.1% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 12.5x enterprise multiple and 4.8% implied options volatility.
Sustained 87.9% gross profitability converts into 46.9% operating margin and 20.1% ROIC, outpacing sector cost of capital.
ROIC: 20.1% // GM: 87.9%YoY revenue trajectory of +10.6% paired with 4.09% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +10.6% // FCF YLD: 4.09%Altman Z-Score of 22.52 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 22.52 // F-SCORE: 9/9Trading at 19.1x trailing P/E (17.8x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 19.1x // EV/EBITDA: 12.5xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $598.72 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 41.9% net margins.
NET MARGIN: 41.9% // D/E: 0.05x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for UTHR & activate live FRED threshold breach alerts.